Advances in™ Endometrial Cancer: Focus on Immunotherapeutic and Molecularly Targeted Strategies

Release Date: November 8, 2019
Expiration Date: November 8, 2020
Media: Internet - based

Activity Overview

Endometrial cancer has the greatest incidence among gynecological malignancies and is the most prevalent cancer in women. Early detection, facilitated by the presence of symptoms in women with stage I disease, leads to a good prognosis, with standard first-line treatments that include surgery and radiotherapy. However, a significant unmet treatment need persists for patients with advanced disease. Immune checkpoint inhibition, molecularly targeted therapies, and combination strategies are being pursued for use in these patient populations.

The Advances in™ Endometrial Cancer: Focus on Immunotherapeutic and Molecularly Targeted Strategies educational activity will aid clinicians in putting into practice a guideline-based approach for managing patients through a series of video interviews with a faculty expert in endometrial cancer. The essentials of disease classification and molecular testing, clinical trial data, current and emerging treatment strategies, and management of treatment-related toxicities will be discussed.

Benefits of Participating

• Increase your knowledge related to the historical and current classifications of endometrial cancer and recognize the role of testing for molecular markers in clinical practice.
• Build confidence in your ability to integrate current and emerging immunotherapeutic and molecularly targeted agents into treatment plans for patients with endometrial cancer.
• Learn strategies to effectively monitor and manage adverse events that occur with current treatments in endometrial cancer, including combination therapies.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Eisai Inc. and TESARO, A GSK Company.

Target Audience

This educational initiative is directed toward medical oncologists, gynecologic oncologists, pathologists, radiation oncologists, and surgical oncologists who treat patients with gynecologic malignancies. Obstetrician/gynecologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, fellows, and other health care professionals interested in the treatment of gynecologic malignancies will also be invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

• Explain guideline recommendations for molecular testing in endometrial cancer to identify clinically significant molecular alterations and how emerging data and techniques may change guidelines in the future.
• Evaluate current and emerging clinical trial data regarding new treatment options and combination strategies for patients with endometrial cancer.
• Integrate emerging data into clinical practice scenarios to improve outcomes for patients with endometrial cancer.
• Identify strategies to monitor and mitigate adverse events associated with current and emerging treatment options for endometrial cancer.

Faculty, Staff, and Planners’ Disclosures

Faculty

Bradley J. Monk, MD, FACS, FACOG
Professor
Division of Gynecologic Oncology
Arizona Oncology (US Oncology Network)
University of Arizona College of Medicine
Creighton University School of Medicine at St. Joseph’s Hospital
Medical Director
US Oncology Research Network - Gynecologic Program
Phoenix, AZ

Disclosures: Consultant: AbbVie, Advaxis, Agenus, Amgen, Aravive, AstraZeneca, Asymmetric Therapeutics, Boston Biomedical, Chemocare, ChemoID, Circulogene, Clovis, Conjupro, Eisai, Geistlich, Genmab/Seattle Genetics, GOG Foundation, ImmunoGen, Immunomedics, Incyte, Janssen/Johnson & Johnson, Laekna Health Care, Mateon (formerly Oxigene), Merck, Mersana, Myriad, NuCana, OncoMed, OncoQuest, OncoSec, Perthera, Pfizer, Precision Oncology, Puma, Regeneron, Roche/Genentech, Samumed, Takeda, Tesaro/GlaxoSmithKline, VBL, Vigeo; Speaker: AstraZeneca, Clovis, Janssen/Johnson & Johnson, Roche/Genentech, Tesaro/GlaxoSmithKline.

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER^® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER^® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER^® is required by ACCME to resolve all COI. PER^® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or the company that provided commercial support.